ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Dolutegravir

Also written as “GSK1349572”, “DTG” and “Dolutegravir 50 mg”.

Its studies are mostly in Infections · HIV Infections · Malaria · Acquired Immunodeficiency Syndrome · Tuberculosis, led by 3 companies.

Drug pageDolutegravir: every studyAll 170 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 13, 201766 company-led studies, 3 open or runningNext primary completion: Sep 14, 2032 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only643 open or runningphase 4since Oct 13, 2017Nov 5, 2007Sep 14, 2032phase 3 · NCT07393659
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Jun 4, 2024Jun 4, 2024none ahead
Viatris10 open or runningearly phase 1since Jul 28, 2021Jul 28, 2021none ahead

Also a collaborator on its studies: PPD Development, LP, Johnson & Johnson and Shionogi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Viatris only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2021First study: early phase 1 study in HIV-1-infectionFirst studyNCT05030025 · 43 enrolled · Canada

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 integrase inhibitor”ChEMBL 37, by rule

Studies

The one study Viatris leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05030025HIV-1-infection · CanadaEarly 1CompletedAug 29, 202143

How it is read

Names in the registry

  • “GSK1349572”, 20 entries
  • “Dolutegravir”, 12 entries
  • “DTG”, 6 entries
  • “Dolutegravir 50 mg”, 4 entries
  • “DTG/3TC”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.